Angiogenesis 2023: What the Talon Phase 3b study results mean for neovascular AMD
February 10th 2023Carl D. Regillo, MD, highlights the Talon Phase 3b results for brolucizumab vs aflibercept in a matched treat-and-extend superiority study for neovascular AMD at the virtual 2023 Angiogenesis conference.
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
September 27th 2022Mr Gokulan Ratnarajan recaps his 2022 ESCRS presentation: "A Real World Comparison Of iStent Combined With Phacoemulsification And Endocyclophotocoagulation (Ice2) With Preserflo And Xen-45 Implants In The UK; Short- And Long-Term Outcomes."
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
July 18th 2022Dr Justis P. Ehlers dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.
Hypersonic vitrectomy a novel technology for removing vitreous
June 29th 2022Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Dr Sunir J. Garg explains how retinal surgeons can remove the vitreous gel with more efficiency.